Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
about
Optimal delivery of male breast cancer follow-up care: improving outcomesA concise review of testosterone and bone healthAdvances in treating metastatic bone cancer: summary statement for the First Cambridge ConferenceThe Individualized Diet and Exercise Adherence Pilot Trial (IDEA-P) in prostate cancer patients undergoing androgen deprivation therapy: study protocol for a randomized controlled trialA systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma.Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer.Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer.Skeletal response to resistance and impact training in prostate cancer survivors.Optimizing bone health and minimizing skeletal morbidity in men with prostate cancerIncreased bone adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic mice.Preventing bone complications in advanced prostate cancerCurrent management of castrate-resistant prostate cancer.Gynaecological aspects of the treatment and follow-up of transsexual men and women.Guidelines for the management of castrate-resistant prostate cancer.Androgen deprivation therapy for prostate cancer: new concepts and concerns.Treatment-related osteoporosis in men with prostate cancer.Estrogenic side effects of androgen deprivation therapy.Management of complications of androgen deprivation therapy in the older man.Utilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy.Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer.Arctigenin in combination with quercetin synergistically enhances the antiproliferative effect in prostate cancer cellsEfficacy and safety of a modular multi-modal exercise program in prostate cancer patients with bone metastases: a randomized controlled trialThe current practice of screening, prevention, and treatment of androgen-deprivation-therapy induced osteoporosis in patients with prostate cancer.Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.Approach to the prostate cancer patient with bone diseaseSex steroids and bone health status in men.Therapy Insight: osteoporosis during hormone therapy for prostate cancer.Biphosphonates in advanced prostate and renal cell cancer--current status and potential applications.Prostate cancer, osteoporosis and fracture risk.Osteoporosis management in prostate cancer patients treated with androgen deprivation therapyBone densitometric assessment and management of fracture risk in Indian men of prostate cancer on androgen deprivation therapy: Does practice pattern match the guidelines?Androgen deprivation in veterans with prostate cancer: implications for skeletal health.Cancer survivorship research: state of knowledge, challenges and opportunities.Some musculo-skeletal sequelae in cancer survivors.A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal OestradiolOptimal bone health management strategies in patients with prostate cancerSkeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy.Zoledronic acid for cancer therapy--induced and postmenopausal bone loss.Causes, consequences, and treatment of osteoporosis in men.
P2860
Q26773195-D1A12987-AA4A-4F30-9E06-258FBD160856Q28066891-568456DD-46CE-4BF1-84EC-5B95F81D86AFQ30439259-2ECAD737-4933-4FC5-883E-6358D0FF4D5EQ30587975-F8EBBEC9-6C17-4BC7-8E38-F6B41B535B8FQ33581390-2485F022-EAB4-4F0F-A994-C77A996863FFQ33594364-9FC48FE4-62B7-4808-A493-AC3C288E8C76Q33789201-0C894755-3AA6-47CA-9254-755984A4A364Q33911381-45F5D579-AFCE-4593-8514-EA0B5A2B7EBCQ34023510-2138F7F7-99C3-4855-8813-8DD3C4612CDDQ34063149-9C3A73D0-5A4C-437A-B107-F4106E3873C4Q34111634-79EB0CF5-3EA6-4801-BC92-BF7D3425253FQ34111641-0CA21DD8-9E73-44D0-A993-7E236FFD53C1Q34132096-659E8C18-5D80-4CD2-A9C4-75D30AE56229Q34384240-F9D74DA1-11B8-48BA-B825-98CE9495EE55Q34617845-0A54C6B9-279D-409D-846F-7B3E370F4890Q34617878-7DA78C74-B9F1-45D1-815A-D355D6582274Q34743239-608A9153-75A1-4C78-9C9F-A3CC3A8033E2Q34782101-0473F00A-2645-428C-BFCE-B80CD14A406EQ34823216-DB193141-315E-46FA-B195-EE52B0941FC8Q34960635-B82116D1-A1ED-468D-9CBA-CD92D45D1255Q34997308-D09EC19B-8756-464E-9ED6-ACCE5DD31355Q35039872-EE8ABB0B-4EF1-4100-9B73-43B39C91AF03Q35704399-EB757930-B526-429F-BBBD-B1A87D6A033CQ35954808-51C9AEF9-AE13-48E2-8DC2-819960127654Q36187103-AF739F59-1023-4C17-B42B-2A63E33C1B75Q36360754-10E4A718-4AAA-4EEA-A6C1-2D51D11DD2FDQ36369307-E919B6B8-BB90-4214-889B-05682C320039Q36395060-7AF56F01-F3E8-4569-AEE9-D8E2D9BBB13EQ36403183-A89A6B1C-FFC7-4230-934E-98431F684574Q36409740-2FB93EC9-C229-482B-88F8-6916649A54A7Q36416751-D6F2D9A4-E33A-4391-B7AD-7EE2142822FCQ36628819-E2D3C535-B519-460C-A22A-C9E0E979423EQ36667394-8D8DD0E1-AA2F-4451-91F3-37F9A0750DFBQ36819541-475EE59C-834C-4DF7-8ED7-BBF40CEBE9F1Q36819570-1AAC60C2-D0D5-4D48-BFF2-9A968F8807F5Q36861650-82D722CA-EBFB-4CEA-8300-81084F738644Q37080734-8A84375C-784B-45D0-8F6A-9CF882C9CE34Q37121645-DE7F896C-25EC-4FFC-992A-D8B8548942BDQ37123420-20474AFA-AC44-4FD3-BE8A-95844130C893Q37134718-AE1F7000-9A39-4D05-99CA-7404F3487013
P2860
Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Osteoporosis in men with prost ...... s for diagnosis and therapies.
@ast
Osteoporosis in men with prost ...... s for diagnosis and therapies.
@en
type
label
Osteoporosis in men with prost ...... s for diagnosis and therapies.
@ast
Osteoporosis in men with prost ...... s for diagnosis and therapies.
@en
prefLabel
Osteoporosis in men with prost ...... s for diagnosis and therapies.
@ast
Osteoporosis in men with prost ...... s for diagnosis and therapies.
@en
P2093
P2860
P356
P1433
P1476
Osteoporosis in men with prost ...... s for diagnosis and therapies.
@en
P2093
Celestia S Higano
Frederick R Singer
Matthew R Smith
Terrence H Diamond
P2860
P304
P356
10.1002/CNCR.20056
P407
P577
2004-03-01T00:00:00Z